Two figures standing at a mountain summit at sunrise

Founder-friendly capital for category-defining medtech companies.

We partner with medtech founders advancing cardiology, neurotech and adjacent technologies through financing, commercialization and strategic growth.

4
Medical Device Exits
$1.25B+
Aggregate Transaction Value
Founder-Friendly
Capital
Operator-Level
Partnership

What Makes Us Different

Built by operators.
Aligned with founders.
Focused on execution.

Metis is an alternative to traditional venture capital, designed from the operator’s seat for founders building the next generation of cardiology and neurotech companies.

Founder Partnership

Aligned capital. Shared incentives. Founder control respected.

Strategic Foresight

Pattern recognition across financing, regulatory, and commercial milestones.

Operational Execution

Hands-on guidance from company formation through scale.

Enduring Value

Build category-defining medtech companies with durable long-term value.

Where We Focus

Concentrated expertise where operator pattern recognition matters most.

Cardiology

Structural heart, electrophysiology and interventional cardiovascular platforms.

Neurotechnology

Neurovascular, neuromodulation and neurosurgical innovation.

Adjacent Medtech

High-impact medical device categories with operator-driven growth potential.

Portfolio

Current Investments & Advisory Activity

Supporting founders with friendly capital, strategic guidance and operational support from the pre-clinical R&D phase through regulatory approval, scaling sales and strategic acquisition.

John Slump, Founder, President & CEO of Metis MedTech

About

An alternative to traditional venture capital, built by an operator.

Metis MedTech was founded on a simple premise: founders building category-defining medical device companies deserve capital and guidance from someone who has done it themselves.

Our work spans financing strategy, regulatory navigation, commercialization and exit pattern recognition, informed by four successful medical device exits and decades of operator-level experience.

John Slump
Founder, President & CEO

News

John Slump Launches Metis MedTech Following Atraverse Medical Acquisition by Johnson & Johnson

Repeat medtech founder and operator behind multiple nine-figure exits launches investment and strategic advisory platform to help founders build, fund and scale medical device companies.

CHICAGO — May 28, 2026 — John Slump, co-founder and former president and CEO of Atraverse Medical, announced the launch of Metis MedTech, an investment and strategic advisory platform for medical device founders. The launch follows the close of Johnson & Johnson’s (NYSE: JNJ) acquisition of Atraverse Medical on May 15, 2026, which strengthens its J&J MedTech cardiac electrophysiology portfolio.

Founder Inquiry

Building a category-defining medtech company?

Submit a founder inquiry. If there’s strategic fit, we’ll be in touch.